Gilead’s Lenacapavir Wins Cofepris Approval as Twice-Yearly HIV PrEP

Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention option.

A pair of teal gate panels swings open as a flat syringe-shaped silhouette passes through into open space, with tiny faceless silhouettes waiting behind it and the Angel of Independence column silhouetted in the background.

PHARMA REGULATION · HIV PREVENTION APPROVAL · SEPTEMBER 26, 2026 · MEXICO

Regulatory clearance and meaningful patient access are not the same event. On September 24, 2026, Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris), the country’s drug and health-products regulator, granted marketing authorization for lenacapavir as a pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) — the first twice-yearly injectable PrEP to receive a Mexican registration, according to Cofepris. The approval places Mexico alongside Brazil, the United States, and European Union member states in having a regulatory pathway for the drug. Whether that pathway translates into public-sector availability depends on procurement and budget decisions that the authorization itself does not resolve.

Lenacapavir, developed by Gilead Sciences, works by targeting the HIV capsid — the protein shell that protects the virus’s genetic material and the enzymes required for replication — disrupting multiple stages of the viral cycle simultaneously. Administered subcutaneously in two injections per year, it offers a dosing interval that no existing oral PrEP regimen matches. The current standard, a daily oral fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), requires uninterrupted daily adherence.

Clinical evidence and the access gap it created

The Cofepris authorization rests on the clinical record established by the PURPOSE 1 and PURPOSE 2 phase-3 trials. In PURPOSE 1, zero new HIV infections were recorded among the 2,134 participants who received lenacapavir, according to Gilead Sciences. PURPOSE 2, which enrolled cisgender men and gender-diverse people, recorded two infections among the 2,179 lenacapavir recipients, per the same source. The World Health Organization (WHO) recommended lenacapavir as an additional PrEP option in July 2025, citing trial results showing efficacy approaching 100%, according to the Pan American Health Organization (PAHO). Both trials were sponsored by Gilead Sciences, the manufacturer of the drug being evaluated.

Mexico’s regulatory history with lenacapavir predates the approval itself. Cofepris authorized the clinical protocol GS-US-528-9023 — corresponding to PURPOSE 2 — in 2023, making Mexico a trial-site country, according to Infobae. That participation did not translate into early access: as of August 2026, Mexico remained outside the voluntary licensing framework that Gilead Sciences has extended to 120 lower-income countries globally, a framework under which generic manufacturers can produce the drug. Médicos Sin Fronteras (MSF), the international medical humanitarian organization, has called for lenacapavir to be made available for no more than $40 per person per year. In the United States, Gilead Sciences charges $28,000 per patient per year for the two annual doses, according to MSF. The gap between those two figures defines the central tension in lenacapavir’s global rollout.

The PAHO mechanism and what it does not guarantee

Nine days before the Cofepris announcement, PAHO, the regional arm of the WHO for the Americas, disclosed a new agreement with Gilead Sciences under which 14 countries — Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay, and Venezuela — may procure lenacapavir through PAHO’s Regional Revolving Funds, according to the PAHO announcement of September 15, 2026. The Revolving Funds are a pooled procurement mechanism that PAHO operates for vaccines and medicines; their inclusion of lenacapavir creates a structured channel between Gilead and national health ministries that did not previously exist for this product in the region.

PAHO’s announcement is explicit on one point: access through the Revolving Funds is ‘subject to applicable national regulatory and programmatic processes.’ For Mexico, the Cofepris registration satisfies the regulatory condition. The programmatic condition — budget allocation, formulary inclusion, and integration into the national HIV prevention program — remains unresolved. The announcement does not specify a price at which lenacapavir will be offered through the Revolving Funds, nor does it disclose a timeline for national procurement decisions. Approximately 140,000 new HIV infections occur annually across Latin America and the Caribbean, according to PAHO, a figure that frames the scale of unmet prevention need the mechanism is designed to address.

The PAHO agreement complements, rather than replaces, the voluntary licensing framework. That framework already covers 24 countries in Latin America and the Caribbean within the broader 120-country global structure, according to PAHO. Mexico, Brazil, Argentina, and Peru — all PURPOSE trial participants — were excluded from the voluntary licensing arrangement, a point that drew protests at the 26th International AIDS Conference (AIDS 2026) held in Rio de Janeiro in July 2026, where MSF called on Gilead Sciences and governments to guarantee global access. The terms applicable to middle-income countries such as Mexico were not disclosed in the available record.

The structural counterargument to an optimistic reading of the Cofepris approval is straightforward: Mexico’s public HIV prevention budget and formulary cycle, not the registration itself, will determine whether lenacapavir reaches the populations for whom adherence to daily oral PrEP is the binding constraint. People living with HIV who face stigma, those with limited access to health facilities, sex workers, and men who have sex with men — the populations for whom a twice-yearly injection offers the greatest practical advantage over a daily pill — are also those least likely to benefit from a drug that is registered but not publicly procured. Health Secretary David Kershenobich Stalnikowitz said in June 2026 that about 128,000 people in Mexico live with HIV without knowing it, as the government set out a strategy targeting 2030, according to Proceso. Whether lenacapavir is incorporated into that prevention strategy, and at what cost to the public system, has not been publicly disclosed.

What to Watch

  1. Whether Mexico’s health ministry announces a procurement price or formulary inclusion for lenacapavir through the PAHO Revolving Funds mechanism, and on what timeline
  2. Whether Gilead Sciences extends voluntary licensing terms to Mexico, Brazil, Argentina, or Peru — the middle-income trial-participant countries currently outside that framework
  3. The pace at which other PAHO Revolving Funds countries complete their own national regulatory and programmatic processes, which will determine whether the September 15 agreement produces regional supply or remains a framework on paper
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The Cofepris registration resolves the easiest part of the access problem. The harder question — at what price, through which program, and for which patients lenacapavir enters Mexico’s public health system — is determined by budget and procurement decisions that a marketing authorization does not compel.

Lenacapavir Access Expansion: Key Dates

July 2025
WHO PrEP recommendation issued
September 15, 2026
PAHO Revolving Funds agreement announced, covering 14 countries
September 24, 2026
Cofepris marketing authorization in Mexico
Sources: PAHO (as of 2026-09-15); Cofepris (as of 2026-09-24)

Why this is relevant

Patients

Lenacapavir’s twice-yearly subcutaneous dosing may be associated with improved adherence among people at risk of HIV who face stigma, limited facility access, or barriers to daily oral regimens — the populations for whom TDF/FTC adherence is most difficult — though public-sector availability in Mexico has not yet been confirmed.

Industry

Gilead Sciences has secured a Cofepris marketing authorization and is named in the PAHO Regional Revolving Funds agreement covering 14 countries, but the procurement price through that mechanism has not been disclosed, and Mexico remains outside the voluntary licensing framework extended to 120 lower-income countries globally.

Payers

Mexico’s national health system faces a formulary and budget decision that the Cofepris registration does not compel; the PAHO agreement is subject to national programmatic processes, and the gap between the US price of $28,000 annually and the $40 per person per year that MSF says the drug should cost suggests significant pricing negotiation lies ahead.

Caregivers

The Mexican government’s estimate that about 128,000 people live with undiagnosed HIV, and its strategy targeting 2030, imply a scaling of prevention infrastructure; whether lenacapavir is incorporated into that program, and at what cost to households or the public system, has not been publicly disclosed.

Sources: El Financiero; Vanguardia; Pan American Health Organization; Gilead Sciences; Médicos Sin Fronteras; Proceso

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related